Inici › Leucèmia › Texas › Houston
Assaigs clínics de Leucèmia a Houston, TX
28 estudis de Leucèmia busquen participants en centres de Houston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
ReclutantEstudi observacional
- Texas Children's Hospital, Houston
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
ReclutantFase 3
- Quetzal Site 6, Houston
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
ReclutantFase 2
- M D Anderson Cancer Center, Houston
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
ReclutantFase 1
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
ReclutantFase 2
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
ReclutantFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
ReclutantFase 2
- MD Anderson Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
ReclutantFase 3
- Research Site, Houston
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
ReclutantFase 1
- Texas Children's Hospital, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
ReclutantFase 1/2
- MD Anderson Cancer Center, Houston
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
ReclutantFase 3
- University of Texas, Houston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
ReclutantFase 2
- Baylor Texas Children's Hospital, Houston
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
ReclutantFase 1/2
- Research Site, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
ReclutantFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
ReclutantFase 2
- University of Texas MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
ReclutantFase 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of Revumenib and Mezigdomide in People With Leukemia
ReclutantFase 1/2
- MD Anderson Cancer Center (Data Collection Only), Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
ReclutantFase 1/2
- Dren Investigational Site, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
ReclutantEstudi observacional
- M D Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
ReclutantEstudi observacional
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
ReclutantFase 2
- M D Anderson Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
ReclutantFase 2/3
- MD Anderson Cancer Center, Houston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
ReclutantFase 1
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Houston
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
ReclutantFase 1
- The University of Texas M.D. Anderson Cancer Center, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Assaigs de Leucèmia en altres ciutats
- Boston, MA25 estudis
- New York City, NY19 estudis
- Los Angeles, CA16 estudis
- Chicago, IL16 estudis
- Durham, NC13 estudis
- Baldwin Park, CA12 estudis
- Columbus, OH12 estudis
- Nashville, TN12 estudis
- Philadelphia, PA12 estudis
- Milwaukee, WI11 estudis
- Atlanta, GA11 estudis
- Seattle, WA11 estudis
Altres estudis a Houston
- Càncer de pulmó de cèl·lules no petites145 estudis
- Càncer de mama126 estudis
- Càncer (tots els tipus)121 estudis
- Càncer metastàtic104 estudis
- Càncer colorrectal102 estudis
- Càncer d'ovari89 estudis
- Leucèmia mieloide aguda85 estudis
- Càncer de pulmó78 estudis
- Càncer de pròstata76 estudis
- Càncer d'endometri68 estudis
- Càncer de pàncrees61 estudis
- Melanoma59 estudis
De ClinicalTrials.gov, dades recuperades el 4 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.